Month: February 2021

NGM Bio Announces Upcoming Oral Presentation of Phase 1 Study of NGM621 in Patients with Geographic Atrophy at Angiogenesis, Exudation, and Degeneration 2021 – Virtual Edition

--Humanized IgG1 monoclonal antibody engineered to potently inhibit complement C3, with the potential for extended every eight-week dosing-- --CATALINA Phase...

Aquestive Therapeutics Strengthens Board of Directors with Appointments of Julie Krop, M.D., and Marco Taglietti, M.D., and Announces Resignation of Douglas K. Bratton from Board of Directors

WARREN, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and...

Avicanna Enters Multi-level Strategic Partnership with Al Harrington’s, Harrington Wellness Inc., to Commercialize re+PLAY™ Branded Products in Canada and the United States

Avicanna Enters Multi-level Strategic Partnership with Al Harrington’s, Harrington Wellness Inc., to Commercialize re+PLAY™ Branded Products in Canada and the...

Orchard Therapeutics Announces Interim Data for OTL-203 Showing Positive Clinical Results in Multiple Disease Manifestations of Mucopolysaccharidosis Type I Hurler Syndrome (MPS-IH)

All eight patients treated with OTL-203 show stable cognitive function, motor function and growth within the normal range at multiple...

error: Content is protected !!